Amylyx Pharmaceuticals, Inc.
A biopharmaceutical company that develops treatments for neurodegenerative diseases, founded in 2013 by two Brown University undergraduates, Joshua Cohen and Justin Klee. Their first drug, Relyvrio (sold as Albrioza in Canada), was approved in 2022 for ALS—the disease that gives the company its name, since "Amy" comes from "amyotrophic" and "lyx" nods to the breakdown of cells the drug targets. The company withdrew Relyvrio from the market in 2024 after a trial showed no clear benefit, though it kept the drug available free to patients already taking it.
Bought 263.2K
Sold 60.6K
Sold 683.3K
Bought 2.30M
Granted 1.50M · Sold 400.5K
Granted 1.50M · Sold 400.6K
Sold 1.40M
Bought 6.6K
Bought 126.3K · Sold 35.0K
Granted 405.4K · Bought 40.0K · Sold 108.4K
Granted 91.7K · Bought 6.8K · Sold 2.4K
Granted 319.7K · Sold 54.4K
Granted 315.1K · Sold 104.5K
Granted 148.6K · Sold 121.0K
Bought 66.9K
Bought 10.0K
Bought 5.0K
Bought 3.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Morningside Venture Investments Ltd +1 co-filer10% owner · 2 transactions | — | 10.68Mas of Jan 2022 | — | 263.2K | — |
| ALS Invest 1 B.V.10% owner · 6 transactions | — | 5.90Mas of Jul 2022 | — | — | 60.6K |
| Morningside Venture Investments Ltd10% owner · 22 transactions | — | 5.00Mas of Aug 2023 | — | — | 683.3K |
| Halvorsen Ole Andreas +7 co-filers10% owner · 2 transactions | — | 4.87Mas of Jan 2022 | — | 2.30M | — |
| Cohen Joshua BCo-Chief Executive Officer, Director · 31 transactions | — | 3.58M | 1.50M | — | 400.5K |
| Klee Justin B.Co-Chief Executive Officer, Director · 30 transactions | — | 3.58M | 1.50M | — | 400.6K |
| Dragsa 96 LLC +8 co-filers10% owner · 16 transactions | — | 1.85Mas of Sep 2022 | — | — | 1.40M |
| Cheng IsaacDirector · 5 transactions | — | 1.42Mas of Jan 2022 | — | 6.6K | — |
| Milne George M JrDirector · 10 transactions | — | 812.9K | — | 126.3K | 35.0K |
| Frates James MChief Financial Officer · 25 transactions | — | 361.6K | 405.4K | 40.0K | 108.4K |
| Olinger MargaretChief Commercial Officer · 8 transactions | — | 276.1Kas of Dec 2023 | 91.7K | 6.8K | 2.4K |
| Bedrosian Camille LChief Medical Officer · 10 transactions | — | 265.3K | 319.7K | — | 54.4K |
| Mazzariello GinaChief Legal Officer · 24 transactions | — | 209.1K | 315.1K | — | 104.5K |
| Yeramian Patrick DChief Medical Officer · 17 transactions | — | 205.6Kas of Jan 2024 | 148.6K | — | 121.0K |
| Firestone KarenDirector · 5 transactions | — | 66.9K | — | 66.9K | — |
| Zeiher Bernhardt GDirector · 1 transaction | — | 10.0Kas of Mar 2025 | — | 10.0K | — |
| Quimi DaphneDirector · 2 transactions | — | 5.0Kas of May 2024 | — | 5.0K | — |
| Fonteyne Paul R.Director · 1 transaction | — | 3.9Kas of Jan 2022 | — | 3.9K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -542.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.